A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

NCT03783442 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

649

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG: Cisplatin
DRUG: Oxaliplatin
DRUG: Fluorouracil (5-FU)
DRUG: Capecitabine
DRUG: Paclitaxel
BIOLOGICAL: Tislelizumab
DRUG: Placebo

Sponsor

BeiGene